Mayank Bansal is a CFA Charterholder and heads the Equity Research team at Kapitales Research, with over 5 years of experience analysing global equity markets. He leads fundamental, data-driven research combining rigorous financial analysis with macro trends.
Diagnostics Leader Holds Its Full-Year Outlook as Shareholders Back Most Resolutions
Source: Kapitales Research
Highlights:
A global pathology and radiology group reaffirmed its FY2027 EBITDA guidance after four months of trading.
Organic revenue grew 4.4% for the year to October, led by strong radiology and Australian pathology growth.
Two share-plan resolutions drew roughly 38% opposing votes, well above the other items at the annual meeting.
Introduction
Healthcare investors turned their attention to Sydney on 19 November 2026, when one of the world's largest diagnostics groups held its annual general meeting. The chief executive used the occasion to update the market on trading and strategy. Sonic Healthcare Limited (ASX: SHL) is currently trading at AU$21.33.
Guidance Reaffirmed
Sonic Healthcare confirmed FY2027 EBITDA guidance of AU$1,950 to AU$2,030 million at constant currency, excluding about AU$30 million of back-office IT transformation costs. Depreciation and amortisation are tracking to the lower half of their ranges, while interest expense is now expected to rise about 8% on the prior year because of higher base rates. The effective tax rate is forecast at around 27%. The guidance excludes property sale gains and assumes no new regulatory changes.
Trading Update
Organic revenue growth for the year to October was 4.4%, in line with expectations. By market, Australian pathology grew 6%, radiology 8%, Germany and the US 4% each, and the UK 4%. Switzerland managed 1% after absorbing a fee cut of around 3% from 1 July. Management flagged continued momentum in advanced diagnostics, direct-to-consumer testing and specialist referrals, plus a new conditional contract to provide pathology services for Mater hospitals in Brisbane. The potential annual impact from US Medicare pricing changes was updated to about AU$24 million, though it remains uncertain whether the changes will occur.
Looking Back at FY2026
The presentation recapped FY2026 revenue of AU$10,867 million, EBITDA of AU$1,933 million and net profit of AU$621 million. Earnings per share reached 125.6 cents and return on invested capital improved to 6.5%. Total dividends were AU$1.08 per share. The company is investing around AU$30 million a year for three years in digital and AI upgrades.
Voting Results
Most resolutions passed comfortably. The remuneration report drew about 90% support. However, approvals tied to the employee option plan and performance rights plan received around 62% and 61% in favour, with roughly 37% to 38% voting against.
Outro
Steady guidance and improving growth rates gave investors reassurance, though the split vote on share plans shows some shareholders want closer scrutiny of incentives. This article is general information only and is not financial advice.
Note: All data presented is based on information available at the time of writing.
Disclaimer for Kapitales Resear
The materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.Disclosure: The information mentioned above has been sourced from the company reports and a third-party database, i.e. Koyfin. Investors are advised to use strict stop-loss to protect their investments in case of any unfavorable/uncertain market events.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
Diagnostics Leader Holds Its Full-Year Outlook as Shareholders Back Most Resolutions
Highlights:
A global pathology and radiology group reaffirmed its FY2027 EBITDA guidance after four months of trading.
Organic revenue grew 4.4% for the year to October, led by strong radiology and Australian pathology growth.
Two share-plan resolutions drew roughly 38% opposing votes, well above the other items at the annual meeting.
Introduction
Healthcare investors turned their attention to Sydney on 19 November 2026, when one of the world's largest diagnostics groups held its annual general meeting. The chief executive used the occasion to update the market on trading and strategy. Sonic Healthcare Limited (ASX: SHL) is currently trading at AU$21.33.
Guidance Reaffirmed
Sonic Healthcare confirmed FY2027 EBITDA guidance of AU$1,950 to AU$2,030 million at constant currency, excluding about AU$30 million of back-office IT transformation costs. Depreciation and amortisation are tracking to the lower half of their ranges, while interest expense is now expected to rise about 8% on the prior year because of higher base rates. The effective tax rate is forecast at around 27%. The guidance excludes property sale gains and assumes no new regulatory changes.
Trading Update
Organic revenue growth for the year to October was 4.4%, in line with expectations. By market, Australian pathology grew 6%, radiology 8%, Germany and the US 4% each, and the UK 4%. Switzerland managed 1% after absorbing a fee cut of around 3% from 1 July. Management flagged continued momentum in advanced diagnostics, direct-to-consumer testing and specialist referrals, plus a new conditional contract to provide pathology services for Mater hospitals in Brisbane. The potential annual impact from US Medicare pricing changes was updated to about AU$24 million, though it remains uncertain whether the changes will occur.
Looking Back at FY2026
The presentation recapped FY2026 revenue of AU$10,867 million, EBITDA of AU$1,933 million and net profit of AU$621 million. Earnings per share reached 125.6 cents and return on invested capital improved to 6.5%. Total dividends were AU$1.08 per share. The company is investing around AU$30 million a year for three years in digital and AI upgrades.
Voting Results
Most resolutions passed comfortably. The remuneration report drew about 90% support. However, approvals tied to the employee option plan and performance rights plan received around 62% and 61% in favour, with roughly 37% to 38% voting against.
Outro
Steady guidance and improving growth rates gave investors reassurance, though the split vote on share plans shows some shareholders want closer scrutiny of incentives. This article is general information only and is not financial advice.
Note: All data presented is based on information available at the time of writing.
Disclaimer for Kapitales Resear
The materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.Disclosure: The information mentioned above has been sourced from the company reports and a third-party database, i.e. Koyfin. Investors are advised to use strict stop-loss to protect their investments in case of any unfavorable/uncertain market events.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au